Trials / Completed
CompletedNCT00808288
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-00610355 | oral, inhaled, dry powder, 600ug, OD |
| DRUG | PF - 00610355 | oral, inhaled, dry powder, 300ug, OD |
| DRUG | PF- 00610355 | oral, inhaled, dry powder, 100ug, OD |
| DRUG | Placebo | oral, inhaled, dry powder, placebo, OD |
| DRUG | Salmeterol | salmeterol, 50ug, BID |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2008-12-15
- Last updated
- 2019-02-06
Locations
75 sites across 12 countries: United States, Argentina, Bulgaria, Croatia, Czechia, Germany, Hungary, Poland, Slovakia, South Africa, Spain, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00808288. Inclusion in this directory is not an endorsement.